Table 5.
Data from network meta‐analysis comparing eight treatmentsa for localised prostate cancer with respect to all‐cause mortality20
| Study | Arm 1 | Events/Total in Arm 1 | Arm 2 | Events/Total in Arm 2 |
|---|---|---|---|---|
| 1 | A | 36/46 | B | 36/49 |
| 2 | A | 183/367 | B | 171/364 |
| 3 | A | 106/348 | B | 83/347 |
| 4 | A | 74/107 | E | 64/107 |
| 5 | B | 15/46 | C | 19/49 |
| 6 | C | 17/109 | D | 15/108 |
| 7 | C | 89/470 | D | 77/466 |
| 8 | C | 40/111 | E | 39/114 |
| 9 | C | 17/150 | F | 15/151 |
| 10 | C | 3/31 | H | 3/33 |
| 11 | C | 13/114 | H | 12/117 |
| 12 | E | 10/197 | F | 8/195 |
| 13 | E | 45/421 | F | 49/422 |
| 14 | E | 13/153 | F | 13/153 |
| 15 | E | 49/331 | F | 43/333 |
| 16 | F | 1/44 | G | 1/47 |
| 17 | F | 3/85 | G | 2/83 |
a
Observational management (A); prostatectomy (B); conventional radiotherapy (C); conventional radiotherapy hypofractionated (D); conformal low‐dose radiotherapy (E); conformal high‐dose radiotherapy (F); conformal low‐dose radiotherapy hypofractionated (G); cryotherapy (H).